News

10.31.19

Press Release

Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019

SEATTLE, Wash. and VANCOUVER, British Columbia, October 31, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019. Company management will host a conference call and live webcast at 8:00am Eastern Time to report financial…

/Read More

10.24.19

Press Release

Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference

SEATTLE, Wash. and VANCOUVER, British Columbia, October 24, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that data from the Phase 2b ORCA-1 trial will be presented at the SRNT-O Inaugural Conference. “Successful Smoking…

/Read More

09.30.19

Press Release

Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

SEATTLE, Wash. and VANCOUVER, British Columbia, September 30, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their maximum tolerated dose (MTD) study. The results indicate a lack of dose-limiting toxicity as defined by protocol criteria…

/Read More

09.13.19

Press Release

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

SEATTLE, Wash. and VANCOUVER, British Columbia, September 13, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on…

/Read More

09.05.19

Press Release

Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

SEATTLE, Wash. and VANCOUVER, British Columbia, September 5, 2019 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the Company will host its first investor day on Friday, September 20, 2019 in New York City. The event will…

/Read More